These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 25561338)
1. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Dunne MW; Puttagunta S; Sprenger CR; Rubino C; Van Wart S; Baldassarre J Antimicrob Agents Chemother; 2015 Apr; 59(4):1849-55. PubMed ID: 25561338 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507 [TBL] [Abstract][Full Text] [Related]
3. Once-weekly dalbavancin versus daily conventional therapy for skin infection. Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age. Bradley JS; Puttagunta S; Rubino CM; Blumer JL; Dunne M; Sullivan JE Pediatr Infect Dis J; 2015 Jul; 34(7):748-52. PubMed ID: 25551831 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Scoble PJ; Owens RC; Puttagunta S; Yen M; Dunne MW Clin Drug Investig; 2015 Dec; 35(12):785-93. PubMed ID: 26458939 [TBL] [Abstract][Full Text] [Related]
6. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Kim A; Kuti JL; Nicolau DP Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250 [TBL] [Abstract][Full Text] [Related]
9. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045 [TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Andes D; Craig WA Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987 [TBL] [Abstract][Full Text] [Related]
11. Dalbavancin: a review. Scheinfeld N Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497 [TBL] [Abstract][Full Text] [Related]
12. Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion. Rappo U; Dunne MW; Puttagunta S; Baldassarre JS; Su S; Desai-Krieger D; Inoue M Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31501147 [TBL] [Abstract][Full Text] [Related]
13. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens. Das B; Sarkar C; Biswas R; Pandey S Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524 [TBL] [Abstract][Full Text] [Related]
14. The role of dalbavancin in skin and soft tissue infections. Bassetti M; Peghin M; Carnelutti A; Righi E Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166 [TBL] [Abstract][Full Text] [Related]
15. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients. Van Matre ET; Teitelbaum I; Kiser TH Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898 [TBL] [Abstract][Full Text] [Related]
16. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. Dorr MB; Jabes D; Cavaleri M; Dowell J; Mosconi G; Malabarba A; White RJ; Henkel TJ J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034 [TBL] [Abstract][Full Text] [Related]
17. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777 [TBL] [Abstract][Full Text] [Related]
18. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Dunne MW; Zhou M; Darpo B Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068 [TBL] [Abstract][Full Text] [Related]
19. Dalbavancin: a new option for the treatment of gram-positive infections. Lin SW; Carver PL; DePestel DD Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624 [TBL] [Abstract][Full Text] [Related]
20. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Dash RP; Babu RJ; Srinivas NR Infect Dis (Lond); 2017 Jul; 49(7):483-492. PubMed ID: 28264598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]